|(Sempermed)_______|___________________|___________________|___________________|
|Sales_____________|______________192.9|______________>100%|_______________77.5|
|EBITDA____________|______________105.3|______________>100%|________________4.8|
|EBIT______________|______________100.2|______________>100%|________________4.3|
Further inquiry note:
Monika Riedel
Director Group Brand Management, Corporate Spokesperson
+43 676 8715 8620
monika.riedel@semperitgroup.com
Judit Helenyi
Director Investor Relations
+43 676 8715 8310
judit.helenyi@semperitgroup.com
www.semperitgroup.com
end of announcement euro adhoc
=-------------------------------------------------------------------------------
Attachments with Announcement:
=---------------------------------------------
http://resources.euroadhoc.com/documents/15/5/10725755/1/2021-05-19_Semperit_Press_Release_Q1_2021.pdf
(END) Dow Jones Newswires
May 19, 2021 01:39 ET (05:39 GMT)